Picture of Fisher & Paykel Healthcare logo

FPH Fisher & Paykel Healthcare Share Price

0.000.00%
nz flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m-2.3%
3m-4.83%
6m+3.6%
1yr-14.78%
Volume Change (%)
10d/3m+16.59%
Price vs... (%)
52w High-14.85%
50d MA-1.35%
200d MA+2.4%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)42.28
PEG Ratio (f)1.89
EPS Growth (f)28.9%
Dividend Yield (f)1.78%
Valuation (ttm)IndustryMarket
Price to Book Value7.89
Price to Tang. Book8.29
Price to Free Cashflow448.63
Price to Sales8.16
EV to EBITDA30.58

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital17.03%
Return on Equity16.2%
Operating Margin21.14%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueNZ$m1,070.41,263.71,971.21,681.71,581.11,726.241,936.5810.02%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+24.56+26.9+82.29-28.15-33.78+1.55+29.98n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Fisher & Paykel Healthcare EPS forecast chart

Profile Summary

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Company’s products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India and others.

Directors

Last Annual
March 31st, 2023
Last Interim
September 30th, 2023
Incorporated
July 27th, 1954
Public Since
November 13th, 2001
No. of Shareholders
28,343
No. of Employees
6,564
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
nz flag iconNew Zealand Stock Exchange
Shares in Issue
580,581,693

FPH Share Price Performance

Upcoming Events for FPH

Full Year 2024 Fisher & Paykel Healthcare Corporation Ltd Earnings Release

Similar to FPH

Picture of Truscreen logo

Truscreen

nz flag iconNew Zealand Stock Exchange

FAQ